Las Vegas, Nevada (PressExposure) September 02, 2009 -- NewMarket Technology, Inc. Honored by Deloitte-Sponsored Tech Titan Fast Tech Award for Growth Over $95 Million
NewMarket Technology, Inc. (Pinksheets:NWMT) has made the 2009 Tech Titans Fast Tech Five-Year Listing by the Metroplex Technology Business Council (MTBC), the largest technology trade organization in Texas. The Tech Titans Fast Tech Award sponsored by Deloitte annually recognizes the fastest-growing technology companies in the DFW Metroplex, based on percentage of revenue growth during five-year or one-year periods.
About NewMarket Technology, Inc. (www.newmarkettechnology.com) NewMarket is a reporting company with audited financial reports filed with the SEC. NewMarket provides systems integration, technology infrastructure services and emerging technology worldwide. NewMarket has a focus on providing technology and support services to rapidly growing economies where technology purchasing is on the rise. In addition to its base of operations in North America, NewMarket has operations today in the growing economies of China, Southeast Asia, Brazil and Northern Latin America. Last year the Company reported over $40 million in revenue from Asia and over $20 million in revenue from Latin America. Overall, NewMarket reported over $95 million in revenue for 2008.
Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease
Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood
About Transgenomic, Inc. Transgenomic, Inc. (OTC BB: TBIO.OB, http://www.transgenomic.com ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVEÂ® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,450 systems have been shipped to customers in more than 30 countries. The SURVEYORÂ® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared to manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomic Services is a CRO for pharmacogenomic, translational research and clinical trials.
About Power3 Medical Products, Inc. Power3 Medical Products, Inc. (OTCBB: PWRM, http://www.power3medical.com ) is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3 Medical operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas.
Sign up to receive FREE Stock-PR alerts from CRWENewswire.com at [http://www.crwenewswire.com/c/stock-pr]
Rule 17B requires disclosure of payment for investor relations. NewMarket Technology Inc. (NWMT.PK) has compensated Crown Equity Holdings, Inc. (CRWE.OB) five thousand dollars ($5,000) and twenty-five thousand dollars ($25,000) in shares of 144 restricted stock for 30 days of advertising and IR/PR services. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for the completion of building a website for Power 3 Medical Products Inc. (PWRM.OB)
We encourage investors to join and receive CRWENewswire.com FREE e-mail news and stock watch alerts at [http://www.crwenewswire.com/c/stock-pr] and view our full disclaimer.